COMPASS Pathways (CMPS) drew fresh attention after confirming its role at the 2026 Neuroscience Education Institute Fall Congress, where it is showcasing COMP360 psilocybin data and its “Change the Tune in TRD” education campaign.
Recent trading shows that momentum around COMPASS Pathways has been volatile, with a 1-day share price return of 3.98% and a 7-day share price return of 3.72% coming after a 30-day share price return that fell 7.18%. At the same time, a year-to-date share price return of 87.48% and a 1-year total shareholder return of 94% point to strong interest building over the longer stretch as investors weigh the NEI Fall Congress news and broader expectations for COMP360.
Scan other mental health and biotech stocks with similar breakout potential by reviewing our hand picked list of 19 high quality undiscovered gems alongside COMPASS Pathways in your research.
COMPASS Pathways has risen over the past year but moved lower over the past month, which raises a practical question for anyone interested. Is the current volatility an entry point, or is it a signal to wait for cheaper levels before next evaluating it against the fundamentals?
Most Popular Narrative: 50% Undervalued
On the most followed view, COMPASS Pathways screens as undervalued, with a narrative fair value of $24.47 against a last close of $12.28. That gap leans heavily on how COMP360 progresses through late stage trials and a potential approval path.
COMPASS Pathways is still reliant on successful completion and outcomes of its Phase III program and on eventual FDA approval, so any delay, unexpected safety concern or less compelling efficacy profile for COMP360 in treatment resistant depression or PTSD could reduce or defer potential product uptake and limit future revenue and earnings.
The company reported cash and cash equivalents of US$186 million against US$31.3 million of debt and expects net cash used in operations for 2025 to be between US$120 million and US$145 million. If trial, regulatory or launch timing shifts, there is a risk of needing additional financing that could dilute shareholders and weigh on earnings per share and future net margins.
See why 13 investors see COMPASS Pathways as 50% undervalued.
Result: Fair Value of $24.47 (UNDERVALUED)
Still, the bullish COMPASS Pathways story hinges on successful Phase III outcomes and timely FDA decisions, along with managing cash burn without heavy extra dilution if timelines slip.
Find out about the key risks to this COMPASS Pathways narrative.
Next Steps
With COMPASS Pathways pulling strong opinions in both directions, this is the moment to pressure test the story yourself, weigh the upside and downside, and decide how those 2 key rewards and 3 important warning signs fit your own risk tolerance.
Looking for more COMPASS Pathways style investment ideas?
Do not stop with COMPASS Pathways. Use the Simply Wall Street Screener to quickly surface other stocks that fit clear themes, risk levels, and balance sheet profiles so you always have fresh ideas on your radar.
- Target potential mispricing by reviewing a focused selection of companies that screen as quality opportunities using the 26 high quality undervalued stocks.
- Prioritize resilience by searching for businesses that combine lower risk scores with more durable profiles through the 32 resilient stocks with low risk scores.
- Zero in on financial strength by evaluating companies with healthier leverage and funding positions via the list of solid balance sheet and fundamentals (24 results).
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com